The University of Oklahoma is the prime contractor for this $493,001 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program IDIQ vehicle held by the National Cancer Institute. The order calls for further testing of a multi-peptide KRAS vaccine for pancreatic cancer prevention, with objectives to determine efficacy in a genetically engineered mouse model and evaluate immune responses to establish correlates of antitumor protection. Major subcontractors include...
This is a firm-fixed-price delivery order awarded by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) under the PREVENT Preclinical Drug Development Program (PREVENT) IDIQ contract. The $1,249,115 award supports a project titled "TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA", which aims to develop a DNA vaccine to prevent the onset of multiple myeloma by targeting the DKK1 protein. This effort falls...
This is a $712,240 firm fixed-price delivery order awarded to SRI International, a non-profit research and development institute, by the National Cancer Institute (NCI). The contract is part of the NCI's Preclinical Prevention Cancer Program and supports the "Optimization and Further Development of Mesothelin Vaccine for the Prevention of Ovarian Cancer" project. This R&D effort focuses on basic biomedical research towards developing a preventive vaccine for ovarian cancer. The...
This federal contract was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (HHS), to the University of Oklahoma (OU) to support the PREVENT Preclinical Drug Development Program. The $884,341.08 firm-fixed-price contract task order is for the development of an EGFR and KRAS vaccine to prevent lung cancer. Key subcontractors include The Methodist Hospital (doing business as Houston Methodist Hospital) and the Medical College of Wisconsin. The...
The University of Texas M.D. Anderson Cancer Center has been awarded a $632,712 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The delivery order is for the task of conducting preclinical efficacy and intermediate biomarker studies to develop an induced pluripotent stem cell-based vaccine for the...
This federal contract award, with an ID of HHSN261201500039I|HHSN26100004, was issued by the National Cancer Institute (NCI) to the Weill Medical College of Cornell University. The $1,246,582.34 Firm Fixed Price award is for the development of an anti-Fusobacterium nucleatum vaccine for colorectal cancer immunoprevention. This contract is part of the NCI's PREVENT Cancer Preclinical Drug Development Program, a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value....
The University of Oklahoma is the prime contractor on a $911,531 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program IDIQ vehicle held by the National Cancer Institute. The scope of work involves testing the efficacy of combination KRAS or EGFR peptide vaccines and the investigational drug CA-170 to improve immunoprevention against lung tumor progression driven by specific mutations in transgenic animal models. Objectives include determining tolerability...
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) for the further development of an induced pluripotent stem cell (iPSC)-based vaccine for colon cancer prevention. The $1,293,012 contract is a task order under the NCI's PREVENT Preclinical Drug Development Program (PREVENT) indefinite delivery/indefinite quantity (IDIQ) contract. MD Anderson, a component of the University of Texas System, is...
The Medical College of Wisconsin, Inc. was awarded a $633,080.38 delivery order against the PREVENT Cancer Program master IDIQ contract to develop multiantigen vaccines preventing lung adenocarcinomas driven by K-Ras or EGFR oncoproteins in mice. The National Cancer Institute, part of the Department of Health and Human Services, issued the award under its PRECLINICAL PREVENT CANCER PROGRAM focused on preclinical efficacy and intermediate endpoint biomarkers. Performance will occur in...
This federal contract was awarded by the National Cancer Institute (NCI) to the Mayo Clinic, a large non-profit academic medical center, to conduct a pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer. The $785,458.00 cost-reimbursement contract has a period of performance through March 31, 2023. Mayo Clinic is serving as the prime contractor and has subcontracted a portion of the work to the University of Pittsburgh, another major research institution....